Although healthcare providers are frequently exposed to prescription drug promotion, they often have not received education on recognizing false or misleading prescription drug promotion. As part of FDA's Bad Ad Program, the Office of Prescription Drug Promotion (OPDP) has developed real-life case studies to help bridge this gap for healthcare providers and trainees.
These real-life case studies below are based on actual Warning and Untitled Letters issued by OPDP to companies regarding alleged false or misleading prescription drug promotion. They are designed for use in a teaching setting. The case studies include the alleged violative promotional material, the Warning or Untitled Letter that was issued, the prescribing information, and a facilitator guide that can be used by an instructor to lead a discussion in a group setting.